• PRM96 - COST-EFFECTIVENESS OF PRECISION ONCOLOGY DECISIONS- CHALLENGES IN METHODOLOGY

    Oct 1, 2018, 00:00

  • PRM230 - A SIMPLE NEW METHOD FOR COMBINING BINOMIAL COUNTS OR PROPORTIONS WITH HAZARD RATIOS FOR EVIDENCE SYNTHESIS OF TIME-TO-EVENT DATA

    Oct 1, 2018, 00:00

  • PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION- ANALYTICS FOR EUROPE

    Oct 1, 2018, 00:00

  • PCN218 - PERSONALIZED THERAPY DEVELOPMENT IN NSCLC DEMONSTRATES INTERSECTION BETWEEN INNOVATION AND POSITIVE COVERAGE DECISIONS

    Oct 1, 2018, 00:00

  • PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES- HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?

    Oct 1, 2018, 00:00

  • PSY210 - HEALTH-RELATED QUALITY OF LIFE AFTER BARIATRIC SURGERY – A PROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN48 - REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP196 - DEVELOPMENT STRATEGIES PROMOTING PHARMACEUTICAL INDUSTRY TO IMPROVE HEALTHCARE MANAGEMENT

    Oct 1, 2018, 00:00

  • PRS64 - RIGHT TO BREATHE, RIGHT TO CHOOSE?

    Oct 1, 2018, 00:00

  • PGI5 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER COLORECTAL SURGERY

    Oct 1, 2018, 00:00

  • PSS51 - ANALYSIS OF TOPICAL PREPARATIONS FOR TREATMENT OF ONYCHOMYCOSIS IN UKRAINE

    Oct 1, 2018, 00:00

  • PRM239 - DOES MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) WORK? RESULTS FROM A SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PIN17 - BUDGET IMPACT ANALYSIS OF LIPOSOMAL AMPHOTERICIN B VERSUS AMPHOTERICIN B LIPID COMPLEX FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS IN A TERTIARY HOSPITAL IN THE KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PIN84 - THE STUDY OF THE CONSUMPTION OF ANTIVIRAL DRUGS USED FOR PHARMACOTHERAPY IN PATIENTS WITH ACUTE RESPIRATORY VIRAL INFECTIONS IN UKRAINE

    Oct 1, 2018, 00:00

  • PND157 - ENHANCEMENT FOR STROKE PATIENT’S OUTCOMES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PMU18 - UK EPIDEMIOLOGY AND CLINICAL BURDEN OF VACCINE-PREVENTABLE CHILDHOOD INFECTIOUS DISEASES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSS14 - BUDGET IMPACT ANALYSIS OF CONBERCEPT AND RANIBIZUMAB IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION IN CHINA

    Oct 1, 2018, 00:00

  • PRM242 - USING NON-RANDOMISED EVIDENCE OR CLINICAL ASSUMPTIONS TO MAKE CONNECTIONS IN NETWORK META-ANALYSIS - A CASE STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PRM233 - THE USE OF THE TWO-STAGE METHOD IN ADJUSTING FOR TREATMENT CROSSOVER. A SIMULATION STUDY.

    Oct 1, 2018, 00:00

  • PCN361 - HEALTH ECONOMIC VALUE PROPOSITIONS FOR SUBCUTANEOUS TRASTUZUMAB AND THEIR TRANSFERABILITY TO CENTRAL-EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCN382 - QUALITY OF LIFE IN LONG-TERM CANCER SURVIVORS- IMPLICATIONS FOR FUTURE HEALTH TECHNOLOGY ASSESSMENTS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PCV45 - BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSION

    Oct 1, 2018, 00:00

  • PHP198 - EVALUATION OF THE SWEDISH EARLY AWARENESS AND ALERT SYSTEM

    Oct 1, 2018, 00:00

  • PIN83 - PHARMACOECONOMIC EVALUATION OF PUBLIC PROCUREMENT CRITERIA IN THE NATIONAL PNEUMOCOCCAL VACCINE IMMUNIZATION PROGRAM- SLOVENIA AS A CASE STUDY

    Oct 1, 2018, 00:00

  • PCN85 - SAVING HEALTHCARE AND SOCIETAL COSTS BY CHANGING THE ROUTE OF ADMINISTRATION OF ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PRM68 - IMPUTATION METHODS FOR MISSING DATA IN COST-UTILITY ANALYSES ALONGSIDE RANDOMIZED CONTROLLED TRIALS- AGGREGATE OR NON-AGGREGATE?

    Oct 1, 2018, 00:00

  • PRM121 - COMPARATIVE IMPACT OF TWO VARICELLA VACCINES ON VARICELLA EPIDEMIC DYNAMICS IN ITALY

    Oct 1, 2018, 00:00

  • PRM149 - OPEN-SOURCE DISCRETE EVENT SIMULATION MODEL FOR MAJOR DEPRESSION DISORDER (MDD)- AN UPDATE SUITABLE FOR NEW GENERATION TREATMENT?

    Oct 1, 2018, 00:00

  • PIN39 - IS THE UNIVERSAL POPULATION HEPATITIS C VIRUS SCREENING A COST-EFFECTIVE STRATEGY? A SYSTEMATIC REVIEW OF THE ECONOMIC EVIDENCE

    Oct 1, 2018, 00:00

  • PSS9 - DRUGS UTILISATION IN THE ITALIAN SETTING- THE CASE OF WAMD, DME AND RVO

    Oct 1, 2018, 00:00

  • PRS28 - COST OF ILLNESS DUE TO BACTERIAL PNEUMONIA IN THE ADULT POPULATION IN DOMINICAN REPUBLIC FROM A PUBLIC PERSPECTIVE DURING 2018

    Oct 1, 2018, 00:00

  • PCN234 - IMPACT OF BALDUZZI LAW (CNN CLASS) ON TIME TO MARKET AND ON PRICES FOR ONCOLOGY DRUGS IN ITALY

    Oct 1, 2018, 00:00

  • PND96 - FOUR-YEAR RESOURCE USE AND COSTS ASSOCIATED WITH ADMINISTRATION AND MONITORING OF DISEASE MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SET

    Oct 1, 2018, 00:00

  • PRM152 - A GENERIC BAYESIAN DES MODEL FOR MULTI-STATE DISEASE PROGRESSION

    Oct 1, 2018, 00:00

  • PRM205 - A CRITIQUE OF YOUTUBE AS A DATA SOURCE FOR THE QUALITATIVE EXPLORATION OF PATIENT REPORTED INFORMATION ON ACUTE MYELOID LEUKEMIA.

    Oct 1, 2018, 00:00

  • PDB126 - FACTORS INFLUENCING FOOD CHOICES OF PEOPLE WITH TYPE 2 DIABETES- A Q METHODOLOGY STUDY

    Oct 1, 2018, 00:00

  • PMU40 - LIVE BIRTH RATE (LBR), ONGOING PREGNANCY RATE (OPR) AND OVARIAN HYPERSTIMULATION SYNDROME (OHSS) RISK WITH ORIGINATOR VERSUS BIOSIMILAR RECOMBINANT FOLLITROPIN ALFA- A POOLED ANALYSIS OF CLINICAL TRIAL DATA

    Oct 1, 2018, 00:00

  • PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PCN25 - ROLE OF PROGRESSION FREE SURVIVAL IN THE APPROVAL PROCESS AND EUROPEAN HTA ASSESSMENTS

    Oct 1, 2018, 00:00

  • PIN59 - ESTIMATING THE COST-EFFECTIVENESS OF ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PHP190 - THE PERCEPTION OF PROFESSIONALS OF HOW PEOPLE WITH DISABILITY ARE PERCEIVED BY THE PUBLIC

    Oct 1, 2018, 00:00

  • PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)

    Oct 1, 2018, 00:00

  • PCN203 - HEALTHCARE RESOURCE USE IN PATIENTS WITH END-STAGE ADVANCED CUTANEOUS T-CELL LYMPHOMA (CTCL)- RESULTS OF SEVEN SEMI-STRUCTURED INTERVIEWS ACROSS LEADING UK CENTRES

    Oct 1, 2018, 00:00

  • PUK6 - A TARGETED REVIEW OF REAL-WORLD DATA SOURCES IN ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD) IN EUROPE

    Oct 1, 2018, 00:00

  • PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLAND

    Oct 1, 2018, 00:00

  • PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN181 - COST-UTILITY ANALYSIS OF ADJUVANT PERTUZUMAB-BASED REGIMEN IN WOMEN WITH HER2-POSITIVE BREAST CANCER IN ITALY

    Oct 1, 2018, 00:00

  • PHP9 - PATIENT INVOLVEMENT IN THE DRUG LIFE CYCLE ACCORDING TO STAKEHOLDERS- EXPLORING THE GAP BETWEEN THEORY AND PRACTICE

    Oct 1, 2018, 00:00

  • PCN91 - PHARMACOECONOMIC EVALUATION OF ENZALUTAMIDE FOR THE TREATMENT OF POST-CHEMOTHERAPY PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN RUSSIA

    Oct 1, 2018, 00:00

  • PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSY112 - FACTOR UTILIZATION ANALYSIS OF EXTENDED DURATION AND STANDARD-ACTING RECOMBINANT FVIII TREATMENTS FOR SEVERE HEMOPHILIA A IN SWEDEN

    Oct 1, 2018, 00:00

  • PRM43 - A COST-UTILITY ANALYSIS OF THE ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM PLUS CATARACT SURGERY IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA IN FRANCE

    Oct 1, 2018, 00:00

  • PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PHP223 - TRERAPEUTIC AREAS, A KEY FACTOR FOR HTA AND REIMBURSEMENT DECISIONS, TIMMING AND ACCESS

    Oct 1, 2018, 00:00

  • PND108 - INSOMNIA IN EVACUATION SHELTERS AFTER THE GREAT EAST JAPAN EARTHQUAKE

    Oct 1, 2018, 00:00

  • PHP162 - LICENCED ORPHAN MEDICINES EXPENDITURE IN TURKEY

    Oct 1, 2018, 00:00

  • PHP52 - ACCESSIBILITY AND ACCESS TO ORPHAN DRUGS IN PORTUGAL- HOW FAR ARE WE?

    Oct 1, 2018, 00:00

  • PCN81 - BUDGET IMPACT ANALYSIS OF CDK4/6 INHIBITORS FOR THE FIRST LINE THERAPHY OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PDB68 - COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PSY138 - COMPARATIVE EFFICACY AND SAFETY OF HYDROMORPHONE AND MORPHINE IN POST-CESAREAN SECTION ANALGESIA- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY102 - MUCOPOLYSACCHARIDOSIS DRUG COVERAGE IN RUSSIA- EXPEDIENCY OF DRUG PROCUREMENT CENTRALIZATION

    Oct 1, 2018, 00:00

  • PIN78 - UPTAKE OF THE SEASONAL INFLUENZA VACCINATION AMONGST A COHORT OF PHARMACISTS IN IRELAND

    Oct 1, 2018, 00:00

  • PIN103 - A SYSTEMATIC REVIEW- COST-EFFECTIVENESS OF VACCINATION WITH NEW MENINGOCOCCAL SEROGROUP B VACCINES

    Oct 1, 2018, 00:00

  • PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY- WHAT’S THE DIFFERENCE?

    Oct 1, 2018, 00:00

  • PND146 - MS PATIENTS’ PERCEPTION OF THE EFFECTS OF PR-FAMPRIDINE ON WALKING DISORDERS AND DAILY LIFE- RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PCN256 - INDICATION-SPECIFIC PRICING IN ONCOLOGY- HOW WILL U.S. PAYERS DETERMINE VALUE AMID THIS GROWING TREND?

    Oct 1, 2018, 00:00

  • PND100 - PRICING OF INNOVATIVE MEDICINES- DO INNOVATIVE SCHEMES OFFER A SOLUTION?

    Oct 1, 2018, 00:00

  • PMU86 - VALUING HEALTH-STATE- AN EQ-5D-5L VALUE SET FOR ETHIOPIANS

    Oct 1, 2018, 00:00

  • PUK14 - LOW-DOSE ORAL DESMOPRESSIN LYOPHILISATE IS A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS EXPERIENCING AT LEAST TWO NOCTURNAL MICTURITIONS

    Oct 1, 2018, 00:00

  • PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • RM1 - SENSITIVITY ANALYSIS FOR NOT-AT-RANDOM MISSING DATA IN TRIAL-BASED COST-EFFECTIVENESS ANALYSIS USING MULTIPLE IMPUTATION

    Oct 1, 2018, 00:00

  • PSY169 - COMPARISON OF EU5 MARKET ACCESS DECISIONS FOR CROHN’S DISEASE BASED ON THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PND91 - HOW ADVANCED THERAPY TREATMENT CENTERS IN THE UK CAN IMPROVE MARKET ACCESS FOR SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY- CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITURE

    Oct 1, 2018, 00:00

  • PSY84 - IMPACT OF HIGH DISCONTINUATION RATES FOR SECUKINUMAB ON AVERAGE COSTS AND COST-EFFECTIVENESS RELATIVE TO OTHER BIOLOGICAL TREATMENTS OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN

    Oct 1, 2018, 00:00

  • PSY217 - INCREMENTAL QUALITY-ADJUSTED SURVIVAL ANALYSIS WHEN NO HEAD TO HEAD DATA ARE AVAILABLE- A CASE STUDY OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ASM)

    Oct 1, 2018, 00:00

  • PMU77 - ANALYSIS OF DECISIONS OF PATIENTS NOT TO PURCHASE PRESCRIPTION MEDICINES. RESULTS OF THE CROSS-SECTIONAL PHARMACY-BASED SURVEY CONDUCTED IN POLAND

    Oct 1, 2018, 00:00

  • PHP95 - THE STUDY OF DYNAMIC ADJUSTMENT MECHANISM OF MEDICAL SERVICE PRICE IN CHINA

    Oct 1, 2018, 00:00

  • PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES- DESPEGA STUDY

    Oct 1, 2018, 00:00

  • PSY141 - SUFENTANIL VERSUS FENTANYL FOR PAIN RELIEF IN LABOR WITH THE COMBINED SPINAL-EPIDURAL ANAESTHESIA - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PND94 - A RETROSPECTIVE DATABASE ANALYSIS OF HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS AMONG PATIENT TREATED WITH RUFINAMIDE IN UK

    Oct 1, 2018, 00:00

  • PUK7 - ASSOCIATION BETWEEN ADHERENCE TO RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES- A POPULATION BASED STUDY USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP175 - EVOLUTION OF THE HEALTHCARE EXPENDITURES BY SERVICES IN HUNGARY BETWEEN 2010 AND 2015

    Oct 1, 2018, 00:00

  • PHP309 - HTA CAPACITY BUILDING - OPPORTUNITIES AND CHALLENGES AS RESULT OF HTA INSTITUTIONS RESEARCH

    Oct 1, 2018, 00:00

  • PMD148 - THE BUDGET IMPACT OF GLOBAL TELEMEDICINE SOLUTION IN FRANCE

    Oct 1, 2018, 00:00

  • DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES- A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PSS22 - ECONOMIC BURDEN OF DISEASE OF HIDRADENITIS SUPPURATIVA IN FINLAND- RESULTS FROM THE HI-FI STUDY

    Oct 1, 2018, 00:00

  • PND122 - HEALTH STATE UTILITIES ASSOCIATED WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS), A RARE GENETIC DISORDER

    Oct 1, 2018, 00:00

  • PRM135 - DICE FOR NICE? LESSONS FROM A SINGLE TECHNOLOGY APPRAISAL

    Oct 1, 2018, 00:00

  • PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS- A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET

    Oct 1, 2018, 00:00

  • PIH41 - ANTIBIOTIC PRESCRIPTION PATTERNS OF PRIMARY CARE PHYSICIANS IN TREATING CHILDREN

    Oct 1, 2018, 00:00

  • PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANY

    Oct 1, 2018, 00:00

  • PMS15 - CHILDHOOD OBESITY IS ASSOCIATED WITH BACK PAIN- A COHORT STUDY OF 466,997 INDIVIDUALS

    Oct 1, 2018, 00:00

  • PHP40 - TRENDS IN THE INCLUSION OF NON-PHARMACEUTICAL HEALTH TECHNOLOGIES IN THE ISRAELI NATIONAL LIST OF HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY

    Oct 1, 2018, 00:00

  • PMU89 - EUROPEAN UNION 5 (EU5) NORMS FOR THE 3-LEVEL EQ-5D (EQ-5D-3L) QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PRM146 - CURRENT AND FUTURE TRENDS IN METHODOLOGIES OF SURVIVAL CURVE EXTRAPOLATION IN ONCOLOGY ACCEPTED BY HTA AUTHORITIES.

    Oct 1, 2018, 00:00

  • PND109 - SICKLE-CELL DISEASE RELATED HOSPITALIZATIONS IN FRANCE - A REGIONAL DESCRIPTIVE ANALYSIS FROM THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE IN 2016

    Oct 1, 2018, 00:00

  • PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PSS38 - LITERATURE REVIEW OF ECONOMIC EVALUATIONS IN RETINAL CONDITIONS

    Oct 1, 2018, 00:00

  • PHP45 - AN INITIAL ANALYSIS OF THE COST-BASED PRICING REVISIONS IN JAPAN

    Oct 1, 2018, 00:00

  • PCN6 - SYSTEMATIC LITERATURE REVIEW OF EFFICACY SAFETY DATA FOR THE TREATMENT OF PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PND17 - PHARMACOEPIDEMIOLOGY OF LATERAL AMIOTROPHIC SCLEROSIS IN BELARUS

    Oct 1, 2018, 00:00

  • PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN

    Oct 1, 2018, 00:00

  • PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES- VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALS

    Oct 1, 2018, 00:00

  • PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

    Oct 1, 2018, 00:00

  • PRM84 - LEVERAGING HOSPITAL-BASED EMR SYSTEMS FOR REAL-WORLD EVIDENCE GENERATION- OPPORTUNITIES AND CHALLENGES

    Oct 1, 2018, 00:00

  • PGI27 - THERAPEUTIC STRATEGIES UTILIZATION AND RESOURCES CONSUMPTION IN PATIENTS AFFECTED BY CROHN DISEASE (CD) OR ULCERATIVE COLITIS (UC) IN AN ITALIAN REAL-WORLD SETTING, VENETO REGION

    Oct 1, 2018, 00:00

  • PIN60 - ECONOMIC EVALUATION OF BCG VACCINATION - A SYSTEMATIC REVIEW AND QUALITY ASSESSMENT

    Oct 1, 2018, 00:00

  • PSS6 - USING RANDOMISED CONTROLLED TRIAL (RCT) DATA AS EXTERNAL CONTROL TO OBTAIN COMPARATIVE EFFECTIVENESS IN A BAYESIAN NETWORK META-ANALYSIS MODEL

    Oct 1, 2018, 00:00

  • PSY40 - ALL-CAUSE MORTALITY INCREASED WITH NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICARE

    Oct 1, 2018, 00:00

  • PRM114 - SYNTHETIC SAMPLE GENERATION OF THE 4S STUDY PLACEBO POPULATION USING A STOCHASTIC RESAMPLING TECHNIQUE

    Oct 1, 2018, 00:00

  • PCN177 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?

    Oct 1, 2018, 00:00

  • PHP104 - PRESCRIPTION DRUG USE AND INAPPROPRIATE PRESCRIBING AMONG PREGNANT WOMEN IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PMU10 - USE OF A LIFETIME SIMULATION MODEL TO QUANTIFY THE IMPACT OF HYPERKALAEMIA ON PREDICTED AND QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE

    Oct 1, 2018, 00:00

  • PCN9 - BRAIN TUMOR RESECTION SURGERY IN PEDIATRIC PATIENTS; RETROSPECTIVE EPIDEMIOLOGICAL STUDY USING JAPANESE ADMINISTRATIVE DATABASE

    Oct 1, 2018, 00:00

  • PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICS

    Oct 1, 2018, 00:00

  • PMD72 - COST-EFFECTIVENESS ANALYSIS OF ADDING SPIROMETRY TO THE NATIONAL SCREENING PROGRAM FOR THE PURPOSE OF COPD CASE FINDING IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PRS39 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY (SITT) VERSUS MULTIPLE INHALER TRIPLE THERAPIES (MITT) TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN CANADA

    Oct 1, 2018, 00:00

  • PRM151 - ASSESSING THE EXTERNAL VALIDITY OF MAPPING ALGORITHMS TO ESTIMATE CHU9D UTILITIES FROM THE PEDSQLTM IN DISPARATE SUB-GROUPS

    Oct 1, 2018, 00:00

  • PMD157 - ASSESSMENT OF IN VITRO DIAGNOSTIC REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES- IDENTIFIED HURDLES AND POSSIBLE SOLUTIONS.

    Oct 1, 2018, 00:00

  • PIN94 - YELLOW FEVER IN COLOMBIA- FROM PUBLIC CALAMITY TO NEGLECTED DISEASE

    Oct 1, 2018, 00:00

  • PMD156 - NEXT GENERATION SEQUENCING- BENEFIT ANALYSIS TO SUPPORT A STRATEGIC ADOPTION MODEL IN THE ITALIAN NHS

    Oct 1, 2018, 00:00

  • PND30 - ECONOMIC IMPACT OF AUTISM SCREENING IN EUROPE

    Oct 1, 2018, 00:00

  • PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS- A RETROSPECTIVE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PRS9 - SWITCHING FROM SUBCUTANEOUS TREPROSTINIL TO INHALED TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION TREATMENT AND ECONOMIC IMPACT EVALUATION

    Oct 1, 2018, 00:00

  • PMD71 - PROCESS ANALYSIS AND SIMULATION MODELING OF A COMPUTED TOMOGRAPHY (CT) OF THE BRAIN FOCUSING ON THE EXPLORATION AND ASSESSMENT OF OPERATIONAL TIME AND COST SAVINGS

    Oct 1, 2018, 00:00

  • PIN88 - HOSPITALIZATION RATES AMONG EMERGENCY ROOM-DIAGNOSED HIV+ PATIENTS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PMU55 - CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE- THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN

    Oct 1, 2018, 00:00

  • PIH19 - CAN THE PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS BE APPLIED IN SURGICAL CARE? - A MODEL FRAMEWORK FOR SURGICAL APPROACHES

    Oct 1, 2018, 00:00

  • PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANY

    Oct 1, 2018, 00:00

  • PRM221 - NETWORK META-ANALYSIS IN THE PRESENCE OF NON-PROPORTIONALITY- A REVIEW OF NICE SUBMISSIONS

    Oct 1, 2018, 00:00

  • PCV97 - HEARTH FAILURE IN VENETO REGION, ITALY- ANALYSIS OF THE THERAPEUTIC PATHWAYS AND CONSUMPTION OF HEALTH CARE RESOURCES

    Oct 1, 2018, 00:00

  • PSY71 - ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY IN ITALY

    Oct 1, 2018, 00:00

  • PCN365 - AN ASSESSMENT OF PATIENT REPORTED OUTCOME (PRO) CLINICAL TRIAL DATA REPORTING, SPECIFIC TO CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP367 - PROFESSIONALS’ PERSPECTIVE OF FACTORS INFLUENCING THE DEVELOPMENT OF A SUCCESSFUL PHARMACEUTICAL PRODUCT. THEMATIC ANALYSIS

    Oct 1, 2018, 00:00

  • PMH73 - THE BURDEN OF TREATMENT-RESISTANT DEPRESSION IN EUROPE FROM THE PATIENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • AC4 - RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALY

    Oct 1, 2018, 00:00

  • PIN36 - PUBLIC HEALTH AND ECONOMIC IMPACT OF GENDER-NEUTRAL HUMAN PAPILLOMAVIRUS (HPV) VACCINATION WITH THE NONAVALENT HPV VACCINE IN BELGIUM (WALLONIA REGION) USING A TRANSMISSION DYNAMIC MODEL

    Oct 1, 2018, 00:00

  • PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPE

    Oct 1, 2018, 00:00

  • PHP189 - NATIONAL MY KANTA PAGES PATIENT PORTAL SERVICE- IMPLEMENTATION, USE AND USERS IN 2010-2017 IN FINLAND

    Oct 1, 2018, 00:00

  • PIN21 - ECONOMIC BURDEN OF CERVICAL SCREENING AND TREATMENT OF HPV-RELATED CERVICAL LESIONS AND CANCERS IN EUROPE

    Oct 1, 2018, 00:00

  • PHP125 - COHORT TEMPORARY AUTHORISATION FOR USE IN FRANCE, FRENCH EXPERIENCE OF EARLY-ENTRY PROGRAM 2014-2018

    Oct 1, 2018, 00:00

  • PSY128 - HOW LONG CAN THE ORPHAN DRUG EXCLUSIVITY PERIOD BE EXTENDED, AND AT WHAT COST?

    Oct 1, 2018, 00:00

  • PND72 - COST-MINIMIZATION ANALYSIS OF TERIFLUNOMIDE AND DIMETHYL FUMARATE FOR TREATMENT OF RELAPSING-REMITTING FORMS OF MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PRM57 - ASSESSMENTS OF ECONOMIC VALUE USING FIVE DIFFERENT ONCOLOGY VALUE FRAMEWORKS (ASCO, ESMO, NCCN, MSKCC, ICER)

    Oct 1, 2018, 00:00

  • PMH4 - PHARMACOECONOMICS OF ATYPICAL ANTIPSYCHOTICS INDUCED METABOLIC SYNDROME- A CRITICAL EVALUATION OF COST IMPLICATIONS AND HEALTH OUTCOMES

    Oct 1, 2018, 00:00

  • PCN90 - COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF NILOTINIB FOR THE SECOND LINE TRATMENT OF CHRONIC MIELOID LEUKEMIA IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PHP159 - PUBLIC HEALTH AND ECONOMIC VALUE OF A NATIONWIDE PATIENT BLOOD MANAGEMENT PROGRAM

    Oct 1, 2018, 00:00

  • PMD120 - HEALTHCARE OUTCOMES OF ONE-STEP DIAGNOSIS IN PATIENTS WITH CHRONIC HEPATITIS C

    Oct 1, 2018, 00:00

  • PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PMU19 - RISK OF COMPLICATIONS FOLLOWING OPEN OR MINIMALLY INVASIVE PULMONARY WEDGE RESECTIONS- A PROPENSITY SCORE ANALYSIS

    Oct 1, 2018, 00:00

  • PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN

    Oct 1, 2018, 00:00

  • PCP32 - INTRODUCTION OF TRIAL-BASED ECONOMIC EVALUATIONS IN UKRAINE- ANALYSIS OF PERSPECTIVES AND BARRIES

    Oct 1, 2018, 00:00

  • PMU107 - DISCRETE CHOICE EXPERIMENTS IN HEALTH ECONOMICS- PAST, PRESENT AND FUTURE

    Oct 1, 2018, 00:00

  • PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PSY55 - COMPARISON OF CLINICAL AND ECONOMIC IMPACT OF PROPHYLAXIS WITH DIFFERENT HEMOPHILIC RECOMBINANT FACTORS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD92 - ECONOMIC EVALUATION OF INSERTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AND SUBSEQUENTLY MODERATE STROKE RISK IN A HIGH-RISK POPULATION IN THE UK

    Oct 1, 2018, 00:00

  • PSY134 - HAS THE NICE HST PROCESS BEEN A SUCCESS? COMPARISON WITH OTHER EUROPEAN HTA BODIES

    Oct 1, 2018, 00:00

  • PIN64 - DOLUTEGRAVIR PLUS LAMIVUDINE FOR THE TREATMENT OF NAÏVE ADULTS LIVING WITH HIV-1- A UK COST-MINIMIZATION ANALYSIS

    Oct 1, 2018, 00:00

  • PMS51 - COST-EFFECTIVENESS OF TOFACITINIB-CONTAINING SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PSY115 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN AUSTRIA

    Oct 1, 2018, 00:00

  • PRM21 - MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION

    Oct 1, 2018, 00:00

  • PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL

    Oct 1, 2018, 00:00

  • PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE- REALITIES, CHALLENGES AND PERSPECTIVES

    Oct 1, 2018, 00:00

  • PND155 - REDUCED RELAPSE RATES AND IMPROVED QUALITY OF LIFE FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS TREATED WITH NATALIZUMAB VS INJECTABLE THERAPIES

    Oct 1, 2018, 00:00

  • Test-Retest Reliability of EQ-5D-5L Valuation Techniques- The Composite Time Trade-Off and Discrete Choice Experiments

    Oct 1, 2018, 00:00

  • PCN214 - IBRITUMOMAB TIUXETAN RADIOLABELLED WITH YTTRIUM CHLORIDE- 4 YEARS OF USE IN THE 37 PUBLIC HOSPITALS OF PARIS AND IN FRANCE

    Oct 1, 2018, 00:00

  • PRS4 - ASSOCIATIONS OF DEPRESSION AND ANXIETY WITH A RISK OF EXACERBATIONS IN ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP

    Oct 1, 2018, 00:00

  • PIH49 - KNOWLEDGE ABOUT MENSTRUAL HYGIENE – TOXIC SHOCK SYNDROME

    Oct 1, 2018, 00:00

  • PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PSY26 - OPIOID PRESCRIBING IN A SOUTH AFRICAN MEDICAL INSURANCE SCHEME SETTING

    Oct 1, 2018, 00:00

  • PCV125 - THE IMPORTANCE OF DEFINING PATIENTS IN HEALTH INSURANCE CLAIMS DATA- FOCUSING ON CARDIOVASCULAR DISEASES

    Oct 1, 2018, 00:00

  • PMH28 - ECONOMIC IMPACT OF EARLY TREATMENT ON LIFETIME COSTS OF ALZHIEMER’S DISEASE IN CZECHIA

    Oct 1, 2018, 00:00

  • PHP253 - WAYS OF IMPROVING PHARMACEUTICAL ASSISTANCE IN UKRAINE THROUGH THE DEVELOPMENT OF PHARMACEUTIST PROTOCOLS

    Oct 1, 2018, 00:00

  • PCV159 - THE IMPACT OF SUBSEQUENT CARDIOVASCULAR (CV) EVENTS ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM208 - VALIDATION OF THE ENGLISH VERSION OF THE ADHERENCE ASSESSMENT QUESTIONNAIRE (AAQ)

    Oct 1, 2018, 00:00

  • PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB23 - THE CLINICAL GAP BETWEEN THE GUIDELINES AND PRACTICE OF STATINS PRESCRIBING AMONG DIABETIC PATIENTS

    Oct 1, 2018, 00:00

  • PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-HN) STUDY

    Oct 1, 2018, 00:00

  • PMU115 - AN INVESTIGATION OF ISSUES IN THE TRANSLATION AND COMPREHENSION OF THE TERMS SELF-CONSCIOUS AND EMBARRASSED IN PATIENT REPORTED OUTCOME (PRO) MEASURES

    Oct 1, 2018, 00:00

  • PMU6 - THE RELATIONSHIP BETWEEN INTEGRATION DISABILITY POLICIES AND INTENTION OF EARLY RETIREMENT WITHIN A CONTEXT OF MULTIMORBIDITY- RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • PCN284 - PRICING AND TIME-TO-MARKET FOR TYROSIN-KINASI INHIBITORS (TKIS) IN ITALY

    Oct 1, 2018, 00:00

  • PUK26 - IMPACT OF EMERGING HIF-PH INHIBITORS ON RENAL ANEMIA TREATMENT

    Oct 1, 2018, 00:00

  • PSY8 - PREVALENCE OF OBESITY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN133 - THE SOCIETAL IMPACT OF OBINUTUZUMAB IN THE FIRST LINE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN GERMANY

    Oct 1, 2018, 00:00

  • PCN312 - HOW HAS THE RELAUNCHED CANCER DRUGS FUND AFFECTED NICE’S APPROVAL OF NOVEL ONCOLOGY TECHNOLOGIES?

    Oct 1, 2018, 00:00

  • PMD187 - COMPARISON OF PERIPHERAL INTRAVENOUS CANNULA DRESSINGS

    Oct 1, 2018, 00:00

  • PHP80 - HOW CLASSIFICATION OF CELL AND GENE THERAPIES AS DRUGS, DEVICES OR PROCEDURES COULD HAVE SIGNIFICANT IMPLICATIONS FOR THEIR PRICING AND REIMBURSEMENT AND COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PRM71 - ESTIMATION OF THE NUMBER OF PNEUMONIA PATIENTS IN JAPAN USING PUBLIC REAL-WORLD DATA

    Oct 1, 2018, 00:00

  • PRM154 - MODELING MIGRAINE DAY FREQUENCY BY RESPONDER STATUS- A RE-ANALYSIS OF DATA FROM ERENUMAB CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PCN272 - ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS- LENALIDOMIDE UTILISATION AND EXPENDITURE IN IRELAND

    Oct 1, 2018, 00:00

  • PSY88 - PHARMACOTHERAPY COSTS FOR PATIENTS WITH ACROMEGALY IN BULGARIA

    Oct 1, 2018, 00:00

  • PHP86 - IMPORTANCE OF CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING FOR NON-LIFE-THREATENING DISEASES

    Oct 1, 2018, 00:00

  • PMU72 - ESTIMATED COSTS OF PIVOTAL TRIALS FOR NOVEL THERAPEUTIC AGENTS APPROVED BY THE FDA, 2015-2016

    Oct 1, 2018, 00:00

  • PRM159 - AN EVALUATION OF SURVIVAL CURVE EXTRAPOLATION TECHNIQUES USING LONG-TERM OBSERVATIONAL CANCER DATA

    Oct 1, 2018, 00:00

  • PMS74 - THE ROLE OF MONITORING COMPLIANCE TO GUIDELINES IN PREVENTING THE RISK OF SECOND FRACTURE AND DEATH IN PATIENTS WITH OSTEOPOROSIS- A RETROSPECTIVE ADMINISTRATIVE DATABASE ANALYSIS.

    Oct 1, 2018, 00:00

  • PSS61 - PROCESS UTILITIES FOR TOPICAL TREATMENT IN ATOPIC DERMATITIS

    Oct 1, 2018, 00:00

  • PCN29 - CONTRIBUTING FACTORS TO LOWER EFFECTIVENESS OF ONCOLOGY DRUGS COMPARED TO THEIR EFFICACY IN CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIES

    Oct 1, 2018, 00:00

  • PHP30 - THE CONTRIBUTION OF NEW PRODUCT ENTRY VS EXISTING PRODUCT INFLATION IN THE RISING COSTS OF PRESCRIPTION DRUGS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMU44 - TOP 10 MOST COSTLY DISEASES IN CHINA- A BIG-DATA DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PIN124 - ASSESSING THE VALUE OF NEW ANTIBIOTICS IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) WITH A FOCUS ON SURGICAL SITE INFECTION (SSI)- A REVIEW OF THE EVIDENCE BASE

    Oct 1, 2018, 00:00

  • PMU108 - INTEGRATION AND PERCEPTION OF EHEALTH IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PSY4 - RESPONSE TO INDUCTION THERAPY, TREATMENT ADVERSE EVENTS AND HEALTHCARE RESOURCE USE IN INCIDENT ANCA-ASSOCIATED VASCULITIS (AAV) PATIENTS

    Oct 1, 2018, 00:00

  • PSY67 - MANAGEMENT COSTS OF CHEMOTHERAPY AND ALLOGENEIC STEM-CELL TRANSPLANT FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE

    Oct 1, 2018, 00:00

  • PRM258 - METHODOLOGICAL APPROACHES FOR CONDUCTING MATCHING-ADJUSTED INDIRECT COMPARISONS INVOLVING MULTIPLE RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PND74 - COST UTILITY MODEL OF BRIVARACETAM IN THE ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET EPILEPTIC SEIZURES IN SPAIN

    Oct 1, 2018, 00:00

  • PHP242 - AN ANALYSIS OF THE TIMELINES THROUGHOUT THE REIMBURSEMENT PATHWAY FOR DRUGS IN IRELAND

    Oct 1, 2018, 00:00

  • PGI40 - THE ROLE OF PERFORMANCE-BASED RISK-SHARING AGREEMENTS IN MINIMISING PAYER UNCERTAINTY WHEN STANDARD OF CARE IS NOT CLEARLY DEFINED; THE EXAMPLE OF CROHN’S DISEASE RELATED COMPLEX PERIANAL FISTULAS

    Oct 1, 2018, 00:00

  • PSY159 - COMPARISON OF ORPHAN DRUG PRICES- BELGIUM VS LUXEMBOURG

    Oct 1, 2018, 00:00

  • PIN70 - INVESTIGATING THE SECONDARY CARE SYSTEM BURDEN OF INFLUENZA HOSPITALISATION IN CLINICAL RISK GROUPS USING THE HES DATABASE

    Oct 1, 2018, 00:00

  • PRS30 - HOSPITAL MANAGEMENT OF ACUTE COPD EXACERBATION AND IMPACT ON HOSPITAL RE-ADMISSION IN FRANCE

    Oct 1, 2018, 00:00

  • PMD147 - CHARACTERIZING HEALTH CARE RESOURCE UTILIZATION AND COSTS FOLLOWING INTRAMEDULLARY FIXATION FOR PERTROCHANTERIC HIP FRACTURE IN A MEDICARE POPULATION

    Oct 1, 2018, 00:00

  • PMD57 - HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH AND WITHOUT INFECTION AFTER INTRAMEDULLARY NAILING FOR A TIBIAL SHAFT FRACTURE IN ENGLAND

    Oct 1, 2018, 00:00

  • PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN’S DISEASE IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PIH52 - AN INVESTIGATION INTO THE CONTENT VALIDITY AND FEASIBILITY OF THE EQ-5D-5L, SF-12, WEMWBS AND ONS-4 IN MEASURING THE QUALITY OF LIFE AND WELLBEING OF OLDER ADULTS.

    Oct 1, 2018, 00:00

  • PHP247 - RISK-BASED CONTRACTING AND U.S. INSURERS- PAYER WILLINGNESS TO PARTICIPATE AND PREFERRED METRICS IN CHRONIC INDICATIONS

    Oct 1, 2018, 00:00

  • PIH35 - HTTPS-//ISPOR.CONFEX.COM/ISPOR/EURO21/RESEARCH/PAPERS/INDEX.CGI?USERNAME=85228PASSWORD=173196

    Oct 1, 2018, 00:00

  • PMD107 - COST-EFFECTIVENESS ANALYSIS OF NEXT GENERATION RENAL DENERVATION THERAPY DEVICES- THRESHOLD ANALYSIS AND PROJECTIONS OF THE SPYRAL HTN-ON MED TRIAL FOR GERMANY

    Oct 1, 2018, 00:00

  • PSS16 - COST PER RESPONDER ANALYSIS OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE AEROSOL FOAM VERSUS NON-BIOLOGIC SYSTEMIC THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PHP60 - PAYER ARCHETYPING – EXPANDING HORIZONS

    Oct 1, 2018, 00:00

  • PCP22 - KILL / REPLACE / REGULATE- MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARE

    Oct 1, 2018, 00:00

  • PSS42 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN MOROCCO

    Oct 1, 2018, 00:00

  • PSY206 - COMPLEMENTARY AND ALTERNATIVE MEDICINE FOR PAIN- USAGE, OUTCOMES AND COST

    Oct 1, 2018, 00:00

  • PCV64 - THE DIRECT RESOURCE USE AND MEDICAL COSTS OF HEART FAILURE IN NOVA SCOTIA, CANADA

    Oct 1, 2018, 00:00

  • PND37 - COST OF MOTOR NEURONE DISEASE IN CYPRUS

    Oct 1, 2018, 00:00

  • PHP272 - QUANTITATIVE ASSESSMENT OF TECHNICAL ERRORS FOUND IN ECONOMIC MODELS SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PSS47 - A COHORT STUDY TO INVESTIGATE THE FACTORS ASSOCIATED WITH THE INTENTION TO USE ILLEGAL DRUG AMONG SAUDI STUDENTS

    Oct 1, 2018, 00:00

  • PHP66 - CURRENT OPPORTUNITIES AND CHALLENGES IN MARKET ACCESS OF E-HEALTH SOLUTIONS

    Oct 1, 2018, 00:00

  • PHP362 - DO ALL RESEARCH GROUPS ALIGN ON THE VALUE OF AN INTERVENTION? CONCORDANCE OF COST-EFFECTIVENESS FINDINGS BETWEEN ICER REPORTS AND OTHER PUBLICATIONS

    Oct 1, 2018, 00:00

  • PND115 - A COMPARISON OF FDA AND EMA GUIDANCE ON MEDICINES FOR THE TREATMENT OF ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PMH53 - THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS- ANALYSIS OF REAL WORLD EVIDENCE FROM THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMH66 - REAL WORLD ANALYSIS EVALUATING FACTORS ASSOCIATED WITH TREAMENT CHANGE IN PARKINSON'S DISEASE PSYCHOSIS

    Oct 1, 2018, 00:00

  • PRM73 - INCREASING NUMBERS OF REAL-WORLD/HEALTH ECONOMIC PUBLICATIONS IN CLINICAL RHEUMATOLOGY JOURNALS OVER THE PAST 15 YEARS

    Oct 1, 2018, 00:00

  • PND153 - ANALYSIS OF RESPONSES TO SF-36V2 ITEMS FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PIN35 - COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRS106 - THE ASSESSMENT THE QUALITY OF LIFE IN CHILDREN WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA, RECEIVING OMALIZUMAB, BY THE HEALTH UTILITIES INDEX AND STANDARDISED PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE(ACCORDING TO THE PEDIAT ...

    Oct 1, 2018, 00:00

  • PSY100 - COST-EFFECTIVENESS ANALYSIS OF SECOND LINE TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS

    Oct 1, 2018, 00:00

  • PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN- FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATA

    Oct 1, 2018, 00:00

  • PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN TUNISIA

    Oct 1, 2018, 00:00

  • PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCER

    Oct 1, 2018, 00:00

  • PSY101 - LONG-TERM COST-EFFECTIVENESS OF EUROFIT VERSUS WAITING LIST

    Oct 1, 2018, 00:00

  • PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTING

    Oct 1, 2018, 00:00

  • PCN343 - KNOWLEDGE ABOUT HUMAN PAPILLOMAVIRUS (HPV) IN PARENTS OF TEENAGE BOYS IN HUNGARY

    Oct 1, 2018, 00:00

  • PSY51 - CLINICAL AND ECONOMIC ASPECTS OF ENZYME REPLACEMENT THERAPY IN RUSSIAN PATIENTS WITH GAUCHER DISEASE TYPE 1

    Oct 1, 2018, 00:00

  • PIN100 - ASSESSMENT OF MALAYSIAN PREGNANT WOMEN’S KNOWLEDGE, ATTITUDE AND BARRIERS TOWARDS INFLUENZA VACCINATION

    Oct 1, 2018, 00:00

  • PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS

    Oct 1, 2018, 00:00

  • PRS40 - COST-EFFECTIVENESS OF THE SQ® GRASS SUBLINGUAL IMMUNOTHERAPY (SLIT) TABLET IN A PAEDIATRIC POPULATION

    Oct 1, 2018, 00:00

  • PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACH

    Oct 1, 2018, 00:00

  • PCN313 - HOSPITAL BASED HEALTH TECHNOLOGY ASSESSMENT PROGRAM AT KING HUSSEIN CANCER CENTER- ASSESSMENT OF FIVE YEARS EXPERIENCE

    Oct 1, 2018, 00:00

  • PMS55 - THE EFFECTS OF MORTALITY ASSUMPTIONS ON THE COST EFFECTIVENESS OF A NEW GOUT TREATMENT

    Oct 1, 2018, 00:00

  • PSY145 - IMPACT OF BIOSIMILAR ENTRY ON PRICE AND UPTAKE OF BRANDED BIOLOGICS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PSY7 - IMPACT OF OBESITY ON GLYCATED HEMOGLOBIN CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PSS34 - COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN SPAIN

    Oct 1, 2018, 00:00

  • PCP51 - OBSERVATIONAL STUDIES COLLECTING PATIENT PREFERENCES AND EXPERIENCES- REGULATORY DIFFERENCES ACROSS COUNTRIES IN EUROPE

    Oct 1, 2018, 00:00

  • PIH9 - BACTERIOLOGICAL PROFILE AND ANTIBIOGRAM OF NEONATAL SEPSIS IN THE NEONATAL INTENSIVE CARE UNIT OF AN EGYPTIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCE

    Oct 1, 2018, 00:00

  • PCN79 - DECISION IMPACT OF A 21-GENE SIGNATURE IN EARLY BREAST CANCER- A NATURAL EXPERIMENT USING ROUTINE DATA

    Oct 1, 2018, 00:00

  • PIN52 - COST-EFFECTIVENESS OF NEEDLE EXCHANGE PROGRAMS IN A SWEDISH SETTING

    Oct 1, 2018, 00:00

  • PCN296 - BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN269 - HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH TREATMENT IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) RELAPSED OR REFRACTORY (R/R) B-CELL PRECURSOR (BCP) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIES

    Oct 1, 2018, 00:00

  • PCV39 - ASSESSMENT OF THE BUDGET IMPACT OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM) FOR TREATING IRON DEFICIENCY ANEMIA IN CONGESTIVE HEART FAILURE PATIENTS IN GREECE

    Oct 1, 2018, 00:00

  • PND159 - DRAMATIC IMPROVEMENT IN TREATMENT ACCEPTANCE OBSERVED IN PATIENTS WITH MULTIPLE SCLEROSIS SWITCHING TREATMENT- A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PRM225 - EVALUATING PREVIOUS MIGRAINE HEADACHE FREQUENCY STATISTICAL MODELLING APPROACHES USING AN INDEPENDENT DATASET FROM THE EVOLVE STUDIES IN EPISODIC MIGRAINE

    Oct 1, 2018, 00:00

  • PDB97 - TYPE 2 DIABETES- OUTCOME OF DRUG TREATMENT IN PATIENTS INITIATING AGLP1 IN 2012- REAL-LIFE STUDY BASED ON SNIIRAM DATA

    Oct 1, 2018, 00:00

  • PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.

    Oct 1, 2018, 00:00

  • PHP315 - HOW FREQUENTLY IS PATIENT EXPERIENCE FORMALLY ASSESSED IN HEALTH TECHNOLOGY ASSESSMENTS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMS67 - DEVELOPMENT OF A PATIENT DECISION AID (PDA) FOR PATIENTS WITH RHEUMATOID ARTHRITIS THAT REDUCES DECISIONAL CONFLICT AND IMPROVES READINESS FOR TREATMENT DECISION MAKING

    Oct 1, 2018, 00:00

  • PHP50 - PRICE REGULATION ORDINANCE IMPACT ON REIMBURSED PRICES FOR MOSTLY PRESCRIBED MEDICINES IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PCN209 - ASSOCIATION BETWEEN AGE FACTORS AND STRATEGIES FOR PROMOTING PARTICIPATION IN GASTRIC AND COLORECTAL CANCER SCREENINGS

    Oct 1, 2018, 00:00

  • PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY- A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PND97 - DEVELOPING STROKE SYSTEM CARE FOR LOW MIDDLE INCOME COUNTRIES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PMH72 - THE BURDEN OF SUICIDAL IDEATION IN EUROPE FROM THE PATIENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • PGI18 - USE OF PEG-COATED COLLAGEN HEMOSTATIC SELANT (HS)® IN PANCREATODUODENECTOMY (PD) SURGERY- INCIDENCE OF POSTOPERATIVE PANCREATIC FISTULA (POF) AND COST-BENEFIT ANALYSIS IN A RETROSPECTIVE STUDY

    Oct 1, 2018, 00:00

  • PSS26 - COST EFFECTIVENESS OF OCRIPLASMIN FOR TREATMENT OF SYMPTOMATIC VITREOMACULAR ADHESION IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PRS65 - ASSESSING THE IMPACT OF CONCURRENT PRESCRIPTION OPIOID USE ON ADHERENCE TO MAINTENANCE MEDICATIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A RETROSPECTIVE CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP137 - CHANGES IN THE NUMBER OF NURSING WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATION

    Oct 1, 2018, 00:00

  • PMU124 - DOES THE CHOICE OF EQ-5D-3L TARIFF MATTER FOR THE EVALUATION OF CHRONIC DISEASES? COMPARATIVE ANALYSIS OF THE POLISH, UK, SLOVENIAN AND EUROPEAN SCORES

    Oct 1, 2018, 00:00

  • PIN57 - ECONOMIC ASSESSMENT OF EFFECTIVENESS AND SAFETY OF COMMON PRACTICE PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN A MULTIDISCIPLINARY HOSPITAL

    Oct 1, 2018, 00:00

  • CP3 - PATIENTS-INTERVENTION-COMPARATORS-OUTCOMES-SETTINGS-TIME-EFFECTS-SENSITIVITY (PICOSTEPS)- REPRESENTING EVIDENCE-BASED HEALTH ECONOMIC EVALUATIONS (EBHEE) IN THE ORDER OF IMPORTANCE

    Oct 1, 2018, 00:00

  • PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5

    Oct 1, 2018, 00:00

  • PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE- RETROSPECTIVE ANALYSIS FR ...

    Oct 1, 2018, 00:00

  • PIN69 - INDIRECT COSTS OF PNEUMOCOCCAL DISEASES IN POLAND- AN ANALYSIS BASED ON ABSENTEEISM DATA FROM SOCIAL INSURANCE INSTITUTION

    Oct 1, 2018, 00:00

  • PRS59 - SOCIAL UNDERSTANDING OF LUNG FUNCTION EXAMINATION IN CHINA- A CROSS-SECTIONAL SURVEY

    Oct 1, 2018, 00:00

  • PND43 - CLINICAL CHARACTERISTICS AFFECTING DIRECT COSTS IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PCN264 - ASSESSMENT OF TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN SPAIN FOLLOWING INITIAL PLATINUM THERAPY FOR RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

    Oct 1, 2018, 00:00

  • PHP304 - INTRODUCTION OF EBM IN MEDICAL PROFESSIONALS' EDUCATION IN BULGARIA, IN ASSOCIATION WITH THE HTA PROCESS - A PILOT STUDY

    Oct 1, 2018, 00:00

  • PCP20 - A MODERN MEDICAL KNOWLEDGE IN MANAGEMENT OF PATIENTS WITH TUBERCULOSIS IN UKRAINE

    Oct 1, 2018, 00:00

  • PCN122 - DRIVERS FOR DIFFERENT TREATMENT COST ESTIMATIONS ACROSS HTA BODIES

    Oct 1, 2018, 00:00

  • PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PHP71 - HOW A NEW INNOVATION ASSESSMENT TOOL RELATES TO RECENT DRUG LAUNCHES FOR SPANISH NATIONAL ACCESS

    Oct 1, 2018, 00:00

  • PHP370 - AMBULATORY CARE TRENDS IN THE EMERGENCY DEPARTMENT

    Oct 1, 2018, 00:00

  • PHP351 - RISK-SHARING OR RISK-SHIFTING? THE EVOLUTION OF PAYER/INDUSTRY AGREEMENTS IN THE ANNUAL PROCESS OF UPDATING THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL

    Oct 1, 2018, 00:00

  • PMD150 - EXPENSIVE COMBINED THERAPIES FOR RARE DISEASES ARE NOT ALWAYS WHAT THEY SEEM- AN ECONOMIC FEASIBILITY AUDIT

    Oct 1, 2018, 00:00

  • HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAM

    Oct 1, 2018, 00:00

  • PSY95 - EXPLORING THE POTENTIAL COST-EFFECTIVENESS OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

    Oct 1, 2018, 00:00

  • CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PSY75 - IS DISEASE AREA A DETERMINANT OF ORPHAN DRUGS PRICES？

    Oct 1, 2018, 00:00

  • PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PMS46 - COST-EFFECTIVENESS OF PRIMARY PREVENTION FOR OSTEOPOROTIC HIP FRACTURES IN ELDERLY WOMEN

    Oct 1, 2018, 00:00

  • PHP288 - INCLUSION OF QUANTITATIVE PREFERENCE DATA TO UNDERSTAND TREATMENT PREFERENCE IN HTA APPLICATIONS IN THE UK

    Oct 1, 2018, 00:00

  • PMH29 - ASSOCIATION BETWEEN HEALTHCARE COSTS AND COMORBIDITY IN PEOPLE WITH DEMENTIA

    Oct 1, 2018, 00:00

  • PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONS

    Oct 1, 2018, 00:00

  • PHP186 - ANALYSIS OF THE PRIVATELY FINANCED HEALTH CARE SERVICES OF HUNGARIAN PUBLICLY FINANCED HOSPITALS ACCORDING TO MEDICAL FIELDS

    Oct 1, 2018, 00:00

  • Focused Ultrasound Thalamotomy and Other Interventions for Medication-Refractory Essential Tremor- An Indirect Comparison of Short-Term Impact on Health-Related Quality of Life

    Oct 1, 2018, 00:00

  • PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLAND

    Oct 1, 2018, 00:00

  • PMD127 - FIRST DO NO HARM? EXPLORING THE INTERPRETATION OF NICE DIAGNOSTIC ASSESSMENTS WITH COST SAVINGS AND QALY LOSS

    Oct 1, 2018, 00:00

  • PMD60 - DEVELOPING A COMPREHENSIVE TREATMENT COST COMPARISON MODEL IN GUILLAIN-BARRE SYNDROME AND MYASTHENIA GRAVIS TO COMPARE THE TOTAL COST OF IVIG BASED TREATMENT VERSUS CENTRIFUGAL THERAPEUTIC PLASMA EXCHANGE

    Oct 1, 2018, 00:00

  • PMH56 - ACCESS TO DEMENTIA TREATMENTS IN ENGLAND; IS THIS REALLY A PRIORITY AREA FOR PRIMARY CARE?

    Oct 1, 2018, 00:00

  • PHP20 - EUROPE-WIDE SPREAD OF CARBAPENEM-RESISTANT BACTERIA- EPIDEMIOLOGY AND DISEASE BURDEN

    Oct 1, 2018, 00:00

  • PHP63 - MEASURES TO FIGHT ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PMS70 - BIOSIMILAR AND ORIGINATOR ETANERCEPT- INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS BETWEEN SWEDISH COUNTIES

    Oct 1, 2018, 00:00

  • PRM95 - DETECTING INCIDENTS OF INJECTION FROM ELECTRONIC MEDICAL RECORDS USING MACHINE LEARNING METHODS

    Oct 1, 2018, 00:00

  • PIN72 - HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED TO THE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS99 - ACUTE EFFECTS OF DYNAMIC STRETCHING AFTER WARM UP ON SPRINTING ABILITY AND AGILITY AMONG ADOLESCENT BASKETBALL PLAYERS

    Oct 1, 2018, 00:00

  • PSY23 - AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE

    Oct 1, 2018, 00:00

  • PDB34 - CHARACTERIZATION OF THE RISK OF DEVELOPING DIABETES MELLITUS THROUGH THE USE OF THE FINDRISC SCALE IN A VOLUNTARY INSURANCE IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA- A POLICY AND PIPELINE REVIEW

    Oct 1, 2018, 00:00

  • PCN294 - THE PATIENT JOURNEY OF MEN WITH LOCALISED PROSTATE CANCER- RESULTS FROM A QUALITATIVE STUDY IN GREECE

    Oct 1, 2018, 00:00

  • PSY168 - EXPLORATORY DEVELOPMENT OF A VALUE FRAMEWORK APPROACH FOR ORPHAN MEDICINES TO INVESTIGATE THE VALUE-PRICE RELATIONSHIP

    Oct 1, 2018, 00:00

  • Does Selecting Covariates Using Factor Analysis in Mapping Algorithms Improve Predictive Accuracy? A Case of Predicting EQ-5D-5L and SF-6D Utilities from the Women’s Health Questionnaire

    Oct 1, 2018, 00:00

  • PCN367 - HEALTH-RELATED QUALITY OF LIFE ON CÁNCER PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PND118 - PERCEPTIONS AND NEEDS OF PATIENTS WITH MIGRAINE IN GREECE- A FOCUS GROUP STUDY

    Oct 1, 2018, 00:00

  • PCP14 - VALUE FRAMEWORKS AND PRICING SETTING; CAN THEY CO-EXIST?

    Oct 1, 2018, 00:00

  • PRM274 - SIDE-L- FRAMEWORK TO ASSESS INCLUSION OF NON-RCT DATA IN SUBMISSIONS

    Oct 1, 2018, 00:00

  • PRM178 - CHALLENGES IN TRANSLATING 'INFLUENZA' AND ITS SYMPTOMS IN 80 LANGUAGES

    Oct 1, 2018, 00:00

  • PRM85 - MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING TO POWER LITERATURE SEARCH FOR TIMELY, MEANINGFUL RESULTS

    Oct 1, 2018, 00:00

  • PRM1 - VALIDATION OF ALTERNATIVE “SURROGATE” CLINICAL ENDPOINTS IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PSY68 - COSTS ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKAEMIA (AML) PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIA

    Oct 1, 2018, 00:00

  • PHP226 - VALUE-BASED PRICING WHEN THE VALUE DIFFERS BETWEEN INDICATIONS – WHAT IS THE GERMAN WAY?

    Oct 1, 2018, 00:00

  • PHP168 - TRUMP’S PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST

    Oct 1, 2018, 00:00

  • PMS83 - COMPARISON OF FRENCH AND GERMAN HTA ASSESSMENTS FOR THREE RECENTLY EVALUATED RHEUMATOID ARTHRITIS DRUGS

    Oct 1, 2018, 00:00

  • PGI36 - OUT-OF-POCKET AND CATASTROPHIC HEALTH EXPENDITURES AMONG HEPATITIS C PATIENTS- RESULTS FROM A MIDDLE-INCOME COUNTRY

    Oct 1, 2018, 00:00

  • PND21 - THE PREVALENCE OF MILD COGNITIVE IMPAIRMENT- A SYSTEMATIC REVIEW AND DATA SYNTHESIS

    Oct 1, 2018, 00:00

  • PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL

    Oct 1, 2018, 00:00

  • PRS47 - PHARMACOECONOMIC ANALISYS OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

    Oct 1, 2018, 00:00

  • PRM200 - STATED PREFERENCES FOR APPROPRIATE CHARACTERISTICS OF CURRENT HEPATITIS C TREATMENT REGIMENS

    Oct 1, 2018, 00:00

  • PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.

    Oct 1, 2018, 00:00

  • PSS29 - SECUKINUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND22 - LEVERAGE EVIDENCE FROM OBSERVATIONAL COHORTS IN THE ELDERLY TO INFORM STUDY DESIGN OF THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY

    Oct 1, 2018, 00:00

  • PRS100 - QUALITY OF LIFE IN CHILDREN WITH CHRONIC DISEASE - SHOULD WE TAKE IT INTO CONSIDERATION?

    Oct 1, 2018, 00:00

  • PRM148 - HEALTH TECHNOLOGY ASSESSMENT AGENCY APPRAISAL OF IMMUNO-ONCOLOGY CURE FRACTION SURVIVAL MODELLING

    Oct 1, 2018, 00:00

  • PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS- A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PCN109 - EVALUATION OF THE FACTORS AFFECTING THE COST OF PALLIATIVE CARE AT A UNIVERSITY HOSPITAL

    Oct 1, 2018, 00:00

  • PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURES

    Oct 1, 2018, 00:00

  • PRM87 - CRITICAL EVALUATION OF VARIOUS DATA MINING ALGORITHMS USED FOR SIGNAL DETECTION IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATION

    Oct 1, 2018, 00:00

  • PIN45 - COST-EFFECTIVENESS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS

    Oct 1, 2018, 00:00

  • PCV1 - NERVOUS SYSTEM DRUGS AND RISK OF ISCHEMIC STROKE- A REAL WORLD DATA CASE-CONTROL STUDY

    Oct 1, 2018, 00:00

  • PHP251 - PUBLIC-PRIVATE CONTRIBUTION TO BIOPHARMACEUTICAL DISCOVERIES- A BIBLIOMETRIC ANALYSIS OF BIOMEDICAL RESEARCH IN UK

    Oct 1, 2018, 00:00

  • PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTS

    Oct 1, 2018, 00:00

  • PRM231 - REPORT OF NETWORK META-ANALYSIS GEOMETRY- A SYSTEMATIC REVIEW AND METRICS RECOMMENDATION

    Oct 1, 2018, 00:00

  • PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE- IMPACT ON HTA OUTCOMES AND PRICE

    Oct 1, 2018, 00:00

  • PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIES

    Oct 1, 2018, 00:00

  • PMU73 - EVIDENCE MAP OF ECONOMIC EVALUATIONS OF EXERCISE THERAPY PUBLISHED SINCE 2015

    Oct 1, 2018, 00:00

  • PRS33 - THE CLINICAL AND ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS IN ALGERIA

    Oct 1, 2018, 00:00

  • PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.

    Oct 1, 2018, 00:00

  • DS3 - REGORAFENIB IN METASTATIC COLORECTAL CANCER- COST-EFFECTIVENESS ANALYSIS BASED ON PROPENSITY SCORE WEIGHTED COHORT OF CZECH REGISTRY

    Oct 1, 2018, 00:00

  • PRS85 - VALIDATION OF AN EASY-TO-COMPLETE QUESTIONNAIRE FOR STUDYING PREDICTORS OF ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2018, 00:00

  • PMD1 - POST-ND-YAG LASER COMPLICATIONS IN CATARACT PATIENTS TREATED FOR POSTERIOR CAPSULAR OPACIFICATION- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PRM138 - THE DIVE FRAMEWORK FOR USING DIFFERENT TYPES OF INFORMATION IN ESTIMATING LIFETIME CLINICALLY PLAUSIBLE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PMU3 - SELF MEDICATION ATTITUDE, KNOWLEDGE, AND PERCEPTION

    Oct 1, 2018, 00:00

  • PRM53 - THE USE OF PROXY MARKERS TO DEFINE DISEASE STAGE IN PATIENTS WITH MALIGNANT MELANOMA- AN OBSERVATIONAL STUDY USING THE HOSPITAL EPISODE STATISTICS (HES) DATABASE IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS

    Oct 1, 2018, 00:00

  • PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS- A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELS

    Oct 1, 2018, 00:00

  • PCN52 - PREVALENCE AND INCIDENCE OF DIFFERENT TYPES OF CANCER IN GERMANY- AN EPIDEMIOLOGICAL ANALYSIS BASED ON CLAIMS DATA OF MORE THAN 2.9 MILLION INSURED PERSONS

    Oct 1, 2018, 00:00

  • PCN239 - NICE AND THE CANCER DRUGS FUND- APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY22 - A REVIEW ON EPIDEMIOLOGY, RISK FACTORS AND TREATMENT PATTERNS IN MODERATE AND SEVERE PAINFUL DIABETIC NEUROPATHY AND POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PCV90 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL HIP REPLACEMENT SURGERY- SYSTEMATIC REVIEW, NETWORK META-ANALYSIS AND COST –UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PMD172 - HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN FRANCE- A COLLABORATION WITH MEDICAL DEVICE MANUFACTURERS OR NATIONAL AGENCY?

    Oct 1, 2018, 00:00

  • PRM100 - WEIGHTED METHOD FOR ESTIMATING INCIDENCE OF HERPES ZOSTER IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PMU87 - HEALTH STATE UTILITY FOR COMORBID CONDITIONS- EVALUATING THE IMPACT OF DIFFERENT ESTIMATION METHODS

    Oct 1, 2018, 00:00

  • PSY94 - COST-EFFECTIVENESS MODEL COMPARING THERAPEUTIC STRATEGIES FOR TREATING IRON DEFICIENCY ANAEMIA (IDA) IN INFLAMMATORY BOWEL DISEASE (IBD)

    Oct 1, 2018, 00:00

  • PHP152 - MECHANISMS OF ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PCN115 - ASSESSING THE ECONOMIC BURDEN AND 30-DAY READMISSION RATES AMONG PATIENTS WITH BLADDER CANCER IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    Oct 1, 2018, 00:00

  • PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • PMD166 - REVIEW OF NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME (MTEP) FOR MEDICAL DEVICES

    Oct 1, 2018, 00:00

  • PMD43 - BUDGET-IMPACT OF A NOVEL SURGICAL IMPLANT FOR PRIMARY OPEN-ANGLE GLAUCOMA FROM A UK HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN257 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) FOLLOWING INITIAL PLATINUM THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)- A MEDICAL RECORD REVIEW IN GERMANY

    Oct 1, 2018, 00:00

  • PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS- A STUDY OF FIVE DEVELOPED COUNTRIES

    Oct 1, 2018, 00:00

  • PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

    Oct 1, 2018, 00:00

  • PMS104 - EFFICIENCY EXAMINATION OF FUNCTIONAL ELECTRICAL STIMULATION IN THE REHABILITATION OF GAIT AMONG POST-STROKE PATIENTS

    Oct 1, 2018, 00:00

  • PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PHP10 - PATIENTS’ INVOLVEMENT IN THE DEVELOPMENT OF TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND THE DESIGN OF CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PCP52 - AN ANALYTICAL FRAMEWORK FOR EFFICACY EVALUATION OF LIGHT THERAPY IN MOOD DISORDERS- THE LINKED MECHANISMS APPROACH

    Oct 1, 2018, 00:00

  • PND6 - CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PCP43 - HEALTH IMPACT MODELLING (HIM)- CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

    Oct 1, 2018, 00:00

  • PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS17 - BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP263 - COST EFFECTIVENESS AND COST UTILITY ANALYSIS STUDIES OF FIXED DOSE COMBINATIONS – A STUDY BASED ON PUBMED DATABASE

    Oct 1, 2018, 00:00

  • PMD158 - REIMBURSEMENT POLICIES AFFECT PATIENT MIGRATION

    Oct 1, 2018, 00:00

  • QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA- A NATIONWIDE SURVEY

    Oct 1, 2018, 00:00

  • PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICING

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54 (current)
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »